| *Sponsored
With Breaking News Out, Low Float (Nasdaq: INBS) Makes An Early Green Statement
*Get Our Updates Faster—Tap Here To Receive SMS Alerts*
December 18th Greetings, Friend!
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is all over our radar as an early green move could draw major attention.
But most importantly, INBS just dropped this breaking news:
Intelligent Bio Solutions Announces Strategic Partnership with Vlepis, Provider of Advanced Sensing and Wearable Patch Technologies, to Drive Innovation in Non-Invasive Screening and Consumer Health Monitoring
Companies to leverage and collaborate on research and development, distribution, and regulatory expertise to accelerate global adoption of intelligent testing technologies
Alliance positions INBS to enter the fast-growing consumer health market, broadening revenue opp's beyond commercial screening
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has entered into a non-exclusive strategic alliance and collaboration agreement with Vlepis Pty Ltd (“Vlepis”), an Australian medical and wellbeing technology company specializing in advanced sensing and wearable patch technologies, which better positions INBS to enter the consumer health monitoring market. Vlepis’ wearable and software-based technologies complement INBS’ existing portfolio, which includes its Intelligent Fingerprinting Drug Testing Solution and the recently added SMARTOX SmarTest Patch that the Company distributes.
The global wearable medical devices market, valued at USD 42.7Bn in 2024 and projected to grow at more than 25% annually to USD 168.3Bn by 2030(1), is driving demand for non-invasive health solutions. INBS and Vlepis plan to combine their strengths to meet this growing market segment.
“This partnership with Vlepis strengthens our ability to develop innovative testing and monitoring technologies for new sectors,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “By combining our non-invasive technologies and commercial expertise with Vlepis’ pioneering wearable solutions, we can accelerate entry into the consumer health monitoring sector - a market with strong international demand and long-term revenue potential.”
...
Read the full article here.
Don't forget. INBS is a tiny float profile.
Tallying fewer than 1Mn shares total in its float, volatility potential could become significantly heightened after today's announcement.
Review my initial (Nasdaq: INBS) report below and consider getting this top biotech idea on your watchlist. -----
Now on radar... Here's a past champ in our crosshairs.
Brought into focus back a over the summer, it originally popped from an open of $1.28 to a high of $2.25 in the short term.
That run of approximately 74% showed how explosive this under-the-radar Nasdaq profile can be.
And after a recent reverse split that has dropped this profile's float below 1Mn shares, this Nasdaq profile now tops our watchlist.
Consider taking a look at: Intelligent Bio Solutions Inc. (Nasdaq: INBS)
Intelligent Bio Solutions Inc. is rapidly emerging as a leader in the medical technology sector, pioneering non-invasive, real-time point-of-care testing solutions that are reshaping how drug screening and diagnostics are conducted worldwide.
With a focus on pain-free, accessible, and accurate testing, the company is positioned at the forefront of a global movement toward more humane and efficient healthcare technologies.
Company Overview
Founded in 2016 and headquartered in New York, Intelligent Bio Solutions Inc. is committed to leveraging advanced technology to develop transformative solutions that improve quality of life.
The company’s mission is to redefine the approach to testing by delivering pain-free, accessible solutions that drive transformative change across healthcare and workplace safety.
Core Technologies and Products
Intelligent Fingerprinting Drug Testing Solution
At the heart of INBS’s innovation is the Intelligent Fingerprinting Drug Testing Solution.
This system utilizes a patented technology that analyzes sweat collected from the fingertips to detect recent drug use-including cann-a-bis, co-caine, o-piate-s, and me-thamp-heta-mine-within the preceding 16–24 hours.
The process is non-invasive, requiring less than a minute for sample collection and delivering results in under ten minutes.
Key advantages include:
- Dignified, Non-Invasive Collection: No need for blood, urine, or saliva samples, reducing discomfort and privacy concerns.
- Rapid Results: Enables timely decision-making in workplace, clinical, and law enforcement settings.
- Portability and Ease of Use: Designed for use in the field, workplaces, and clinics, with minimal training required.
- Hygienic and Cost-Effective: Reduces biohazard risks and maintenance costs, with annual calibration sufficing for ongoing use.
Regulatory Milestones And U.S. Market Entry
A significant milestone was achieved with the submission of the FDA 510(k) pre-market notification for the Intelligent Fingerprinting Drug Screening System in December 2024.
The company’s clinical studies have demonstrated high sensitivity, specificity, and usability, with performance data showing 94.1% accuracy and pharmacokinetic studies confirming the reliability of fingerprint sweat as a matrix for drug detection.
INBS is on track for a planned expansion into the multi-Bn dollar U.S. market in 2026, targeting a region that accounts for approximately 28% of the global drug screening market.
The rising rates of drug positivity in the U.S. workforce-particularly in safety-sensitive industries-underscore the urgent need for effective, rapid, and non-invasive testing solutions like those offered by INBS.
Intellectual Property and Competitive Position
INBS’s technology is protected by a robust intellectual property portfolio, including six U.S. patents covering the lateral flow test strip, sample collection cartridge, cartridge housing, and buffer clip design.
This IP protection strengthens the company’s competitive position as it prepares for broader commercialization and future product development.
Market Opp. And Future Outlook | 
Tidak ada komentar:
Posting Komentar